CA3209082A1 - Substituted pyrrolopyrimidine and pyrazolopyrimidine as bruton's tyrosine kinase (btk) degraders - Google Patents
Substituted pyrrolopyrimidine and pyrazolopyrimidine as bruton's tyrosine kinase (btk) degraders Download PDFInfo
- Publication number
- CA3209082A1 CA3209082A1 CA3209082A CA3209082A CA3209082A1 CA 3209082 A1 CA3209082 A1 CA 3209082A1 CA 3209082 A CA3209082 A CA 3209082A CA 3209082 A CA3209082 A CA 3209082A CA 3209082 A1 CA3209082 A1 CA 3209082A1
- Authority
- CA
- Canada
- Prior art keywords
- amino
- piperazin
- dioxopiperidin
- piperidin
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163145126P | 2021-02-03 | 2021-02-03 | |
| US63/145,126 | 2021-02-03 | ||
| PCT/US2022/014830 WO2022169798A2 (en) | 2021-02-03 | 2022-02-02 | Substituted pyrrolopyrimidine and pyrazolopyrimidine as bruton's tyrosine kinase (btk) degraders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3209082A1 true CA3209082A1 (en) | 2022-08-11 |
Family
ID=80447078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3209082A Pending CA3209082A1 (en) | 2021-02-03 | 2022-02-02 | Substituted pyrrolopyrimidine and pyrazolopyrimidine as bruton's tyrosine kinase (btk) degraders |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20240132502A1 (https=) |
| EP (2) | EP4501327A3 (https=) |
| JP (1) | JP2024505558A (https=) |
| KR (1) | KR20230142539A (https=) |
| CN (1) | CN117042769A (https=) |
| CA (1) | CA3209082A1 (https=) |
| DK (1) | DK4039688T3 (https=) |
| ES (1) | ES3010513T3 (https=) |
| FI (1) | FI4039688T3 (https=) |
| MX (1) | MX2023008865A (https=) |
| WO (1) | WO2022169798A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202317099A (zh) * | 2020-09-10 | 2023-05-01 | 美商絡速藥業公司 | 用於製備(s)-5-胺基-3-(4-((5-氟-2-甲氧基苯甲醯胺基)甲基)苯基)-1-(1,1,1-三氟丙烷-2-基)-1h-吡唑-4-甲醯胺之方法及中間體 |
| CN118434717A (zh) * | 2021-12-20 | 2024-08-02 | 西格马-奥尔德里奇有限责任公司 | 化学接头 |
| WO2024169871A1 (zh) * | 2023-02-17 | 2024-08-22 | 江苏威凯尔医药科技有限公司 | Btk抑制剂及其用途 |
| WO2024244888A1 (zh) * | 2023-05-26 | 2024-12-05 | 广东弘烨医药科技有限公司 | 9元杂芳基化合物、含其的药物组合物及其制备方法和应用 |
| AU2024298923A1 (en) | 2023-07-25 | 2026-01-22 | Monte Rosa Therapeutics Ag | Substituted piperidinediones for targeted protein degradation |
| CN120535526A (zh) * | 2024-02-26 | 2025-08-26 | 中国药科大学 | 直接结合蛋白酶体的非泛素依赖型蛋白水解靶向嵌合体NuTAC及其应用 |
| WO2026040951A1 (zh) * | 2024-08-19 | 2026-02-26 | 深圳市塔吉瑞生物医药股份有限公司 | 靶向btk蛋白降解靶向嵌合体类化合物及其组合物及用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5114946A (en) | 1987-06-12 | 1992-05-19 | American Cyanamid Company | Transdermal delivery of pharmaceuticals |
| US4818541A (en) | 1987-08-19 | 1989-04-04 | Schering Corporation | Transdermal delivery of enantiomers of phenylpropanolamine |
| CN105017256A (zh) * | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
| CN106146511A (zh) * | 2015-04-03 | 2016-11-23 | 安润医药科技（苏州）有限公司 | 吡唑并嘧啶衍生物、制备方法、药物组合物及用途 |
| JP7337502B2 (ja) * | 2015-09-16 | 2023-09-04 | ロクソ オンコロジー， インコーポレイテッド | がんの治療のためのｂｔｋ阻害剤としてのピラゾロピリミジン誘導体 |
| ES2965081T3 (es) * | 2016-07-07 | 2024-04-11 | Daewoong Pharmaceutical Co Ltd | Derivados 4-aminopirazolo[3,4-d]pirimidinil-azabiciclo y composición farmacéutica que comprende dichos derivados |
| TW201811795A (zh) * | 2016-08-24 | 2018-04-01 | 美商亞闊股份有限公司 | 胺基－吡咯并嘧啶酮化合物及其用途 |
| EP3765026A4 (en) * | 2018-03-10 | 2021-12-22 | Yale University | BTK PROTEOLYSIS MODULATORS AND METHODS FOR USE |
| WO2020023851A1 (en) * | 2018-07-26 | 2020-01-30 | Yale University | Bifunctional substitued pyrimidines as modulators of fak proteolyse |
| CN113544130B (zh) * | 2019-05-31 | 2024-01-09 | 西藏海思科制药有限公司 | 一种btk抑制剂环衍生物及其制备方法和药学上的应用 |
| WO2020252397A1 (en) * | 2019-06-12 | 2020-12-17 | Baylor College Of Medicine | Small molecule proteolysis-targeting chimeras and methods of use thereof |
| CN112812100B (zh) * | 2019-11-18 | 2022-04-05 | 四川海思科制药有限公司 | 一种具有降解btk激酶的化合物及其制备方法和药学上的应用 |
| CN112979656A (zh) * | 2019-12-12 | 2021-06-18 | 上海美志医药科技有限公司 | 一类靶向降解btk蛋白的化合物 |
-
2022
- 2022-02-02 EP EP24204895.7A patent/EP4501327A3/en active Pending
- 2022-02-02 CA CA3209082A patent/CA3209082A1/en active Pending
- 2022-02-02 MX MX2023008865A patent/MX2023008865A/es unknown
- 2022-02-02 EP EP22154786.2A patent/EP4039688B1/en active Active
- 2022-02-02 US US18/263,656 patent/US20240132502A1/en active Pending
- 2022-02-02 FI FIEP22154786.2T patent/FI4039688T3/fi active
- 2022-02-02 WO PCT/US2022/014830 patent/WO2022169798A2/en not_active Ceased
- 2022-02-02 US US17/591,051 patent/US11530222B2/en active Active
- 2022-02-02 ES ES22154786T patent/ES3010513T3/es active Active
- 2022-02-02 KR KR1020237029298A patent/KR20230142539A/ko active Pending
- 2022-02-02 JP JP2023546433A patent/JP2024505558A/ja active Pending
- 2022-02-02 CN CN202280022626.5A patent/CN117042769A/zh active Pending
- 2022-02-02 DK DK22154786.2T patent/DK4039688T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| CN117042769A (zh) | 2023-11-10 |
| US20220259207A1 (en) | 2022-08-18 |
| ES3010513T3 (en) | 2025-04-03 |
| EP4039688B1 (en) | 2024-10-09 |
| DK4039688T3 (da) | 2025-01-02 |
| EP4039688A3 (en) | 2022-11-23 |
| WO2022169798A2 (en) | 2022-08-11 |
| JP2024505558A (ja) | 2024-02-06 |
| EP4039688A2 (en) | 2022-08-10 |
| MX2023008865A (es) | 2023-08-31 |
| FI4039688T3 (fi) | 2024-12-19 |
| EP4501327A3 (en) | 2025-10-15 |
| KR20230142539A (ko) | 2023-10-11 |
| US20240132502A1 (en) | 2024-04-25 |
| US11530222B2 (en) | 2022-12-20 |
| WO2022169798A3 (en) | 2022-09-22 |
| EP4501327A2 (en) | 2025-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021218041B2 (en) | Polycyclic TLR7/8 antagonists and use thereof in the treatment of immune disorders | |
| CA3209082A1 (en) | Substituted pyrrolopyrimidine and pyrazolopyrimidine as bruton's tyrosine kinase (btk) degraders | |
| JP7754865B2 (ja) | Ｔｌｒ７／８アンタゴニストおよびそれらの使用 | |
| JP7125385B2 (ja) | Ｔｌｒ７／８アンタゴニストおよびそれらの使用 | |
| US20240208909A1 (en) | Substituted quinoline derivatives having sos1 inhibition activities and uses thereof | |
| WO2021252339A1 (en) | Substituted purine-2,6-dione compounds as kras inhibitors | |
| CA3147902A1 (en) | Heterobicyclic amides as inhibitors of cd38 | |
| CA3109192A1 (en) | Pyrrolopyrimidine itk inhibitors | |
| KR20250065894A (ko) | Brm 표적화 화합물 및 연관된 사용 방법 | |
| CA3217380A1 (en) | Nampt inhibitors and uses thereof | |
| JP7812861B2 (ja) | サイクリン依存性キナーゼ７（ｃｄｋ７）阻害剤としての三環式ピリミジン | |
| JP2020531556A (ja) | オレキシン受容体拮抗薬としての置換２−アザビシクロ［３．１．１］ヘプタンおよび２−アザビシクロ［３．２．１］オクタン誘導体 | |
| JP7281834B2 (ja) | Ｐｄ－ｌ１拮抗薬化合物 | |
| CA3054459A1 (en) | Azetidine derivative | |
| AU2020413555B2 (en) | PD-L1 antagonist compound | |
| US20240132464A1 (en) | Heterocyclic compounds as e3 ligase inhibitors | |
| WO2026072966A2 (en) | Pi3k degrader compounds and uses thereof | |
| WO2026060424A1 (en) | Akt degrader compounds and uses thereof | |
| WO2025240539A1 (en) | Cdk degrader compounds | |
| HK40058270A (en) | Pd-l1 antagonist compound | |
| BR112020007589B1 (pt) | Inibidores da atividade de proteína canal receptor de potencial transiente 6 (trpc6) ou seu sal farmaceuticamente aceitável, seu uso, e composição farmacêutica | |
| GB2558975A (en) | New compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241205 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241205 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241205 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20251205 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251205 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260203 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260203 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260206 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260316 |